Table 1 Patient and tumor characteristics
Discovery cohort | Validation cohort | |
|---|---|---|
Total number of patients | 172 | 164 |
Analyzed with Illumina HT12 v4 | 172 | 0 |
Analyzed with targeted nCounter panel | 172 | 164 |
Included in the final analysis | 168 | 139 |
Radically operated on (clear margins) | ||
Yes | 168 (100%) | 139 (100%) |
No | 0 | 0 |
Extensive intraductal component (EIC) | ||
Yes | 9 | 7 |
No | 109 | 90 |
Missing | 50 | 42 |
Ipsilateral breast tumor recurrence (IBTR) | ||
Yes | 68 | 62 |
No | 100 | 77 |
Tumor size mm, median (min-max) | 18 (3-45) | 17 (3-35) |
Lymph node status | ||
Node negative | 125 (78%) | 108 (78%) |
Node positive | 35 (22%) | 29 (22%) |
Missing | 8 | 2 |
Estrogen receptor (ER) status | ||
Positive | 119 (71%) | 118 (85%) |
Negative | 49 (29%) | 21 (15%) |
Histological grade | ||
1 | 16 (17%) | 12 (19%) |
2 | 46 (50%) | 24 (39%) |
3 | 30 (33%) | 26 (42%) |
Missing | 76 | 77 |
Subtype | ||
Luminal A | 70 (42%) | 60 (43%) |
Luminal B | 42 (25%) | 29 (21%) |
Basal-like | 37 (22%) | 12 (9%) |
Human epidermal growth factor receptor 2 (HER2)-enriched | 19 (11%) | 38 (27%) |
Radiotherapy | ||
Yes | 116 (69%) | 119 (86%) |
No | 52 (31%) | 20 (14%) |
Chemotherapy | ||
Yes | 34 (20%) | 31 (23%) |
No | 133 (80%) | 105 (77%) |
missing | 1 | 3 |
Endocrine therapy | ||
Yes | 60 (35%) | 91 (65%) |
No | 108 (65%) | 46 (35%) |
missing | 0 | 1 |
Follow-up time | ||
Median time (range) to IBTR in cases, years | 3.7 (0.7-18.7) | 4.4 (0.1-22.5) |
Median follow-up time (range) in controls, years | 13.2 (3.0-19.6) | 12.6 (1.7-26.0) |